Innovation for a Purpose

"When you can not breathe, nothing else matters"

Developing innovative best-in-class therapies to help patients with obstructive airway diseases breathe easily.

CILA Therapeutics is developing a proprietary, first-in-class dry powder microsphere for the treatment of obstructive airway diseases

Persistent Airway Plugs: A Call for Clinical Recognition and Novel Therapies

At CILA, we are working to create a future where patients with obstructive airway diseases have access to an effective therapy to improve and maintain normal airway function, protect the integrity of the lung and prevent ongoing and long-term lung damage.

Currently, there are no effective therapies for the treatment of mucus plugs that make breathing difficult and prevent other inhaled therapies from reaching their target and being effective. CILA is committed to developing therapies to clear mucus obstruction.


April 10, 2023

CILA CEO selected as 2023 Termeer Foundation Fellow

BOSTON, April 10, 2023 — The Termeer Foundation is proud to announce the Class of 2023 Termeer Fellows. The Class of 2023 include Safia Rizvi, CILA Therapeutics; and 19 other outstanding entrepreneurs. Information about the Class of 2023 can be found.
April 26, 2023

CILA to present at Align Summit

CILA Therapeutics was selected to present at the @MassBio Align Summit w/ insights by @McKinsey. The day will include keynotes, panel discussions, and pitches from other innovative seed/series A Biotech and MedTech start-ups.